Key Findings
Roche announced on September 22, 2026, that its investigational once-weekly dual GLP-1/GIP receptor agonist, enicepatide (development code CT-388), achieved favorable topline results in a Phase II clinical trial. The study targeted adult patients living with type 2 diabetes and concurrent overweight or obesity. Enicepatide demonstrated dose-dependent and clinically significant improvements in both glycemic control and body weight over a 48-week treatment period, with the highest dose group achieving an average HbA1c reduction of 2.65% and a mean body weight reduction of 15.5%.
Technical/Clinical Details
Enicepatide (CT-388) is a dual agonist designed to activate both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. GLP-1 receptor agonists are known for their glucose-lowering and weight-reducing effects, while GIP receptor agonism is believed to further augment these benefits through enhanced insulin secretion and direct actions on adipose tissue. This dual targeting strategy aims for superior metabolic improvements.
Key details from the Phase II topline results:
- Patient Population: Adults with type 2 diabetes and overweight or obesity.
- Dosing Frequency: Once-weekly administration.
- Primary Endpoints Met: Significant, dose-dependent reductions in both HbA1c and body weight were observed over 48 weeks.
- Specific Outcomes for Highest Dose (24 mg) Group:
- HbA1c Reduction: An average decrease of 2.65% from baseline, indicating a potent glucose-lowering effect that is competitive with, or potentially superior to, many existing therapies.
- Body Weight Reduction: An average decrease of 15.5% from baseline, representing a substantial weight loss that could set a new benchmark in obesity management.
- Safety Profile: The report indicated a “favorable safety profile,” with detailed safety data to be released in due course.
These results suggest that enicepatide may offer superior efficacy compared to existing single GLP-1 receptor agonists and other diabetes/obesity treatments.
Background & Context
Type 2 diabetes and obesity are intertwined global health epidemics with escalating prevalence. GLP-1 receptor agonists have emerged as transformative therapies in recent years, demonstrating remarkable efficacy in both glycemic control and weight reduction. The development of dual agonists targeting both GLP-1 and GIP receptors represents the next frontier, promising enhanced synergistic effects beyond those of single agonists. Roche’s strong Phase II results position it as a significant contender in this rapidly evolving and highly competitive market.
Strategic Significance & Outlook
The compelling Phase II results for enicepatide strongly support its progression into Phase III clinical trials. Should these results be replicated with a maintained favorable safety profile in larger trials, enicepatide has the potential to become a leading therapeutic agent, reshaping the treatment paradigm for type 2 diabetes and obesity. Roche’s success with enicepatide would establish it as a key player in the expanding GLP-1/GIP market. For patients, this could mean access to a more potent and comprehensive treatment option for effectively managing both blood glucose and body weight, improving long-term health outcomes and quality of life.
Source: https://www.roche.com/media/releases/med-cor-2026-09-22
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments